In CKD, recurrent CV risk is driven not only by traditional factors, particularly diabetes, but also by markers of vascular injury and inflammation, and strategies targeting both metabolic and inflammatory pathways may be critical to reducing recurrent CV burden.
Eunjeong Kang, Dha Woon Im, Minsang Kim et al.· JN. Journal of Nephrology (M...· 0 citations
Single-nucleus transcriptomic profiling of human kidney biopsy tissues reveals disease-specific and shared cellular programs across major glomerular diseases and identifies disease-associated cell states that may contribute to disease progression.
Sehoon Park, Jeong Ho Joo, Yaerim Kim et al.· Kidney International Reports· 0 citations
The CatBoost-based ML model accurately predicts 5-year mortality in non-dialysis CKD patients using five readily available clinical parameters and it is expected that the clinical implementation of this model may offer a practical method for early risk stratification and personalized management.
Sang-He-On Suh, Hong-Sang Choi, C. Kim et al.· Kidney Research and Clinical...· 0 citations
Higher UPCR levels were strongly associated with accelerated CKD progression and shorter projected time to reach the eGFR threshold for kidney failure, underscoring the prognostic significance of proteinuria in patients with advanced CKD.
C. Park, H. J. Hong, Hyungwoo Kim et al.· American Society of Nephrolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.